Earnings Call Summary | MAYNE PHARMA GROUP LIMITED(MAYNF.US) Q2 2024 Earnings Conference
Earnings Call Summary | MAYNE PHARMA GROUP LIMITED(MAYNF.US) Q2 2024 Earnings Conference
The following is a summary of the Mayne Pharma Group Limited (MAYNF) Q2 2024 Earnings Call Transcript:
以下是梅恩製藥集團有限公司（MAYNF）2024年第二季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Mayne Pharma reported a gross profit of $105.8 million, reflecting a margin increase from 52% to 56%. Direct expenses were only up by 1% despite costs for growth and new products.
An underlying EBITDA of $8 million was reported, showing a significant improvement from the same period in the previous year.
Cash balance stands at $146.8 million, down from $220.1 million as of June.
The company achieved four out of five financial goals it set for itself for fiscal year 2024.
梅恩製藥公佈的毛利爲1.058億美元，利潤率從52％增長到56％。儘管有增長和新產品的成本，但直接支出僅增長了1％。
報告的基礎息稅折舊攤銷前利潤爲800萬美元，與去年同期相比有顯著改善。
現金餘額爲1.468億美元，低於6月份的2.201億美元。
該公司實現了自己爲2024財年設定的五個財務目標中的四個。
Business Progress:
業務進展：
Women's Health saw a 45% increase in revenue, with a 96% increase in NEXTSTELLIS revenue specifically.
The company showed discipline in relation to channel liabilities, and new product launches have been significant.
Mayne Pharma remains focused on eliminating non-value adding costs and growing through differentiated products.
Positive trends in Dermatology and Women's Health business units greatly contributed to the overall growth.
The acquisition of RHOFADE for $8 million led to $8 million in revenue and $7.3 million margins in the first three months of ownership.
女性健康的收入增長了45％，特別是NEXTSTELLIS的收入增長了96％。
該公司在渠道負債方面表現出紀律，新產品的發佈意義重大。
Mayne Pharma仍然專注於消除非增值成本，並通過差異化產品實現增長。
皮膚科和女性健康業務部門的積極趨勢極大地促進了整體增長。
以800萬美元收購RHOFADE在所有權的前三個月帶來了800萬美元的收入和730萬美元的利潤率。
More details: MAYNE PHARMA GROUP LIMITED IR
更多詳情： 梅恩製藥集團有限公司
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。